Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Aug;16(2):188–190. doi: 10.1111/j.1365-2125.1983.tb04984.x

Lack of evidence for polymorphism in metoprolol metabolism.

D B Jack, M Wilkins, C P Quarterman
PMCID: PMC1427977  PMID: 6615692

Abstract

The claim for polymorphism in the metabolism of metoprolol is based on a logical fallacy. A frequency distribution of metoprolol AUC data is presented and, although highly skewed, no evidence of more than a single population is apparent. Plasma and urine metoprolol and metabolite data are also presented to support this.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borg K. O., Carlsson E., Hoffmann K. J., Jönsson T. E., Thorin H., Wallin B. Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):125–135. doi: 10.1111/j.1600-0773.1975.tb03329.x. [DOI] [PubMed] [Google Scholar]
  2. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  3. Gulaid A. A., James I. M., Kaye C. M., Lewellen O. R., Roberts E., Sankey M., Smith J., Templeton R., Thomas R. J. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.). Biopharm Drug Dispos. 1981 Apr-Jun;2(2):103–114. doi: 10.1002/bdd.2510020202. [DOI] [PubMed] [Google Scholar]
  4. Jack D. B., Kendall M. J., Dean S., Laugher S. J., Zaman R., Tenneson M. E. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Biopharm Drug Dispos. 1982 Jan-Mar;3(1):47–54. doi: 10.1002/bdd.2510030107. [DOI] [PubMed] [Google Scholar]
  5. Jack D. B., Quarterman C. P., Zaman R., Kendall M. J. Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol. 1982;23(1):37–42. doi: 10.1007/BF01061375. [DOI] [PubMed] [Google Scholar]
  6. Kendall M. J., Brown D., Yates R. A. Plasma metoprolol concentrations in young, old and hypertensive subjects. Br J Clin Pharmacol. 1977 Aug;4(4):497–499. [PMC free article] [PubMed] [Google Scholar]
  7. Kendall M. J., John V. A., Quarterman C. P., Welling P. G. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol. Eur J Clin Pharmacol. 1980 Feb;17(2):87–92. doi: 10.1007/BF00562615. [DOI] [PubMed] [Google Scholar]
  8. Kendall M. J., Quarterman C. P., Jack D. B., Beeley L. Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol. 1982 Jul;14(1):120–122. doi: 10.1111/j.1365-2125.1982.tb04948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560. doi: 10.1056/NEJM198212163072505. [DOI] [PubMed] [Google Scholar]
  10. Lennard M. S., Silas J. H., Freestone S., Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1982 Aug;14(2):301–303. doi: 10.1111/j.1365-2125.1982.tb01982.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Melander A., Danielson K., Scherstén B., Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther. 1977 Jul;22(1):108–112. doi: 10.1002/cpt1977221108. [DOI] [PubMed] [Google Scholar]
  12. Quarterman C. P., Kendall M. J., Jack D. B. The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol. 1981 Mar;11(3):287–294. doi: 10.1111/j.1365-2125.1981.tb00536.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Quaterman C. P., Kendall M. J., Welling P. G. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation. Eur J Clin Pharmacol. 1979 Mar 26;15(2):97–103. doi: 10.1007/BF00609871. [DOI] [PubMed] [Google Scholar]
  14. Regårdh C. G., Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet. 1980 Nov-Dec;5(6):557–569. doi: 10.2165/00003088-198005060-00004. [DOI] [PubMed] [Google Scholar]
  15. Regårdh C. G., Johnsson G., Jordö L., Sölvell L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):45–58. doi: 10.1111/j.1600-0773.1975.tb03321.x. [DOI] [PubMed] [Google Scholar]
  16. Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES